Antibodies against Claudin 18.2 useful in cancer diagnosis

Patent metadata

Field	Value
Publication number	US-9512232-B2
Application number	US-201314397244-A
Country	US
Kind code	B2
Filing date	May 6, 2013
Priority date	May 9, 2012
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.

First claim

The invention claimed is:

1. An antibody selected from the group consisting of:
(i) an antibody produced by or obtainable from a clone deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 5-22A),
(ii) an antibody which is a chimerized or humanized form of the antibody under (i), and
(iii) an antibody comprising the antigen binding site of the antibody under (i), or an antigen-binding fragment of the antibody under (i) or (ii).

2. The antibody of claim 1 , wherein the antigen binding site of the antibody under (i) comprises the variable region of the antibody under (i).

3. A hybridoma deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 35-22A).

4. A method for detecting CLDN18.2 or determining the quantity of CLDN18.2 in a sample comprising the steps of:
(i) contacting a sample with the antibody or antigen-binding fragment thereof of claim 1 and
(ii) detecting the formation of a complex or determining the quantity of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2.

5. A method for determining whether cells express CLDN18.2 comprising the steps of:
contacting a cellular sample with the antibody or antigen-binding fragment thereof of claim 1 and
(ii) detecting the formation of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2 expressed by cells in said sample.

6. A method for diagnosis, detection or monitoring of cancer comprising the steps of:
contacting a biological sample with the antibody or antigen-binding fragment of claim 1 and
(ii) detecting the formation of a complex and/or determining the quantity of a complex between the antibody or the antigen-binding fragment or the conjugate and CLDN18.2.

7. A method for determining whether a cancer is treatable by a cancer therapy targeting CLDN18.2 comprising the steps of:
contacting a sample comprising cancer cells with the antibody or antigen-binding fragment thereof of claims 1 and
(ii) detecting the formation of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2.

8. A diagnostic test kit which comprises the antibody or antigen-binding fragment thereof of claim 1 .

9. A conjugate comprising an antibody or antigen-binding fragment thereof of claim 1 coupled to at least one detectable label.

10. A hybridoma or a recombinant cell capable of producing the antibody or antigen-binding fragment thereof of claim 1 .

11. An antibody produced by or obtainable from a clone deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 35-22A).

Assignees

• Ganymed Pharmaceuticals Ag
• Tron—Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität M
• Tron—Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität M

Inventors

• Sahin Ugur
• Türeci Özlem
• Mitnacht-Kraus Rita
• Wöll Stefan

Classifications

• A61P37/00 Primary

  Drugs for immunological or allergic disorders · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07K16/30 Primary

  from tumour cells · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K16/3023

  Lung · CPC title